Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conventional vs Accelerated CXL for Keratoconus
NCT02883478Phase 2Unknown
- Sponsor
- Oslo University Hospital
- Start
- Aug 2012
- Primary completion
- Aug 2016
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Maximum Corneal Curvature at 2 years, Uncorrected Visual Acuity at 2 years and 3 more. Status: unknown.
Beyond the preview
Go deeper on NCT02883478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02883478.